AlerisLife (ALR) 22Q1 Update

22Q1 Loss of $0.30 in Line with Expectations; Katie Potter Steps Down as CEO; ALR Hires Alvarez & Marsal to Conduct a Comprehensive Operational Review

AlerisLife reported a 22Q1 net loss of $9.7 million or $0.31 per diluted share, slightly better than its 21Q4 loss of $10.6 million or $0.34 per share.  I had estimated a $0.28 loss.

Although ALR’s performance was essentially in line with my expectations, there were a few surprises.  Quarter-end occupancy declined sequentially in both owned and managed senior living communities for the second consecutive quarter.  However, this was offset by solid increases in revenue per occupied room (RevPOR).  Operating costs were higher than anticipated, but general and administrative costs were lower.  Amounts due from Diversified Healthcare Trust (DHC), ALR’s affiliate and owner of its 120 managed communities increased, as did self-insurance liabilities.

Prior to the earnings release, ALR announced that CEO Katie Potter has resigned.  Jeffrey Leer, ALR’s CFO, has become its interim CEO.  The Board of Directors has hired the healthcare consulting practice of Alvarez & Marsal (A&M), a professional services firm known primarily for financial restructuring, to conduct a comprehensive operational view.  Following ALR’s issuance of $63 million of secured debt, which was largely a defensive move intended to assure its liquidity during what is likely to be an extended period of operating losses, the resignation of Ms. Potter and hiring of A&M probably signal a likely scaling back of ALR’s expansion strategy.

With the continuing losses, the management transition and the hiring of A&M, ALR’s share price has suffered another steep decline, falling 41% since my last report to $1.27, far worse than the 12.0% decline in the S&P SmallCap 600 Index.  The decline reflects the concern that changes implemented as a result of A&M’s operational review may permanently impair the value of ALR’s common equity.  Although other possible strategic shifts could allow ALR shareholders to recover some of those losses, ALR remains a highly speculative bet.

Based upon the 22Q1 results, my projections for 2022 and 2023 are little changed.  I anticipate that ALR will report a loss of $1.02 in 2022, narrowing to a loss of $0.46 in 2023.  At this time, I am refraining from reinstating a performance rating and price target on ALR’s stock; probably at least until A&M’s conclusions and recommendations from its operational review are disclosed.  Those result will probably be discussed when ALR releases its 22Q2 earnings report in August.

This is a summary of my latest update report on AlerisLife (ALR). For a copy of the full report, please reach out to me.

May 12, 2022

Stephen P. Percoco
Lark Research
839 Dewitt Street
Linden, New Jersey 07036
(908) 975-0250

© 2015-2024 by Stephen P. Percoco, Lark Research.   All rights reserved.

This blog post (as with all posts on this website) represents the opinion of Lark Research based upon its own independent research and supporting information obtained from various sources. Although Lark Research believes these sources to be reliable, it has not independently confirmed their accuracy. Consequently, this blog post may contain errors and omissions. Furthermore, this blog post is a summary of a recent report published on this subject and that report provides a more complete discussion and assessment of the risks and opportunities of any investment securities discussed herein. No representation or warranty is expressed or implied by the publication of this blog post. This blog post is for informational purposes only and shall not be construed as investment advice that meets the specific needs of any investor. Investors should, in consultation with their financial advisers, determine the suitability of the post’s recommendations, if any, to their own specific circumstances. Lark Research is not registered as an investment adviser with the Securities and Exchange Commission, pursuant to exemptions provided in the Investment Company Act of 1940. This blog post remains the property of Lark Research and may not be reproduced, copied or similarly disseminated, in whole or in part, without its prior written consent.

This entry was posted in ALR, DHC, Health Care and tagged . Bookmark the permalink.